DeepMed Research

MALLINCKRODT UK FINANCE LLP

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Impact of Acthar on Everyday Life of Participants With Severe Keratitis

Phase 4

Completed

Conditions: Keratitis

Interventions: Drug: Acthar

First Posted Date: 2019-11-19

Last Posted Date: 2021-08-18

Lead Sponsor: Mallinckrodt

Target Recruit Count: 36

Registration Number: NCT04169061

Locations: 🇺🇸
Cornea and Cataract Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸
Global Research Management, Inc., Glendale, California, United States
🇺🇸
Eye Research Foundation, Newport Beach, California, United States

and more 6 locations

MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function

Phase 3

Withdrawn

Conditions: Hepatic Encephalopathy

Interventions: Drug: MNK-6105
Drug: Placebo
Drug: Standard of Care

First Posted Date: 2019-10-16

Last Posted Date: 2021-09-22

Lead Sponsor: Mallinckrodt

Registration Number: NCT04128462

MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)

Phase 2

Completed

Conditions: Hepatic Cirrhosis
Hepatic Encephalopathy (HE)

Interventions: Drug: MNK6106
Drug: Rifaximin

First Posted Date: 2018-10-19

Last Posted Date: 2021-07-20

Lead Sponsor: Mallinckrodt

Target Recruit Count: 50

Registration Number: NCT03712280

Locations: 🇺🇸
Global Clinical Professionals, Saint Petersburg, Florida, United States
🇺🇸
Inland Empire Clinical Trials, Rialto, California, United States
🇺🇸
Southern California Research Center, Coronado, California, United States

and more 2 locations

Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)

Phase 4

Terminated

Conditions: Panuveitis
Uveitis, Posterior
Uveitis, Intermediate

Interventions: Drug: Acthar Gel

First Posted Date: 2018-09-04

Last Posted Date: 2021-08-03

Lead Sponsor: Mallinckrodt

Target Recruit Count: 5

Registration Number: NCT03656692

Locations: 🇺🇸
Blue Ocean Clinical Research, Clearwater, Florida, United States
🇺🇸
Bergstrom Eye Research, LLC, Fargo, North Dakota, United States
🇺🇸
Valley Retina Institute, PA, McAllen, Texas, United States

and more 5 locations

Acthar Gel in Participants With Pulmonary Sarcoidosis

Phase 4

Completed

Conditions: Sarcoidosis, Pulmonary

Interventions: Drug: Acthar Gel
Drug: Placebo

First Posted Date: 2017-10-25

Last Posted Date: 2023-02-27

Lead Sponsor: Mallinckrodt

Target Recruit Count: 55

Registration Number: NCT03320070

Locations: 🇺🇸
Central Florida Pulmonary Group PA, Orlando, Florida, United States
🇺🇸
Valley Medical Group, Ridgewood, New Jersey, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

and more 26 locations

Registry to Evaluate INOmax in Newborn Babies With Pulmonary Hypertension

Terminated

Conditions: Pulmonary Hypertension of Newborn

Interventions: Drug: INOmax

First Posted Date: 2017-04-27

Last Posted Date: 2020-06-18

Lead Sponsor: Mallinckrodt

Target Recruit Count: 140

Registration Number: NCT03132428

Locations: 🇺🇸
Loma Linda University Health Care, Loma Linda, California, United States
🇺🇸
University of Chicago Comer Children's Hospital, Chicago, Illinois, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

and more 27 locations

Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Terminated

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Acthar
Drug: Placebo

First Posted Date: 2017-03-03

Last Posted Date: 2020-10-14

Lead Sponsor: Mallinckrodt

Target Recruit Count: 143

Registration Number: NCT03068754

Locations: 🇺🇸
University of California Irvine Medical Center, Orange, California, United States
🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 66 locations

Single-Dose PK Study of an Oxycodone/Acetaminophen Solution in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Oral solution OC/APAP

First Posted Date: 2016-11-17

Last Posted Date: 2017-04-05

Lead Sponsor: Mallinckrodt

Target Recruit Count: 18

Registration Number: NCT02966860

Locations: 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States

Acthar Gel for Active Systemic Lupus Erythematosus (SLE)

Phase 4

Completed

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: Acthar Gel
Drug: Placebo Gel

First Posted Date: 2016-11-03

Last Posted Date: 2020-08-20

Lead Sponsor: Mallinckrodt

Target Recruit Count: 172

Registration Number: NCT02953821

Locations: 🇺🇸
Center for Rheumatology Immunology and Arthritis, Fort Lauderdale, Florida, United States
🇺🇸
Sun Research Institute, San Antonio, Texas, United States
🇲🇽
IBIOMED Research Unit Aguascalientes, Aguascalientes, Mexico

and more 36 locations

Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis

Phase 4

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Placebo
Drug: Acthar Gel

First Posted Date: 2016-09-29

Last Posted Date: 2020-03-31

Lead Sponsor: Mallinckrodt

Target Recruit Count: 259

Registration Number: NCT02919761

Locations: 🇺🇸
June DO, PC, Lansing, Michigan, United States
🇺🇸
Physician Research Collaboration, LLC, Lincoln, Nebraska, United States
🇲🇽
SMIQ, Querétaro, Mexico

and more 55 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy